Scoop: MPM backs a new check­point in­hibitor biotech in $80M raise

An MPM Cap­i­tal-backed biotech based on the dis­cov­ery of a new im­mune check­point in­hibitor has se­cured about $80 mil­lion in fi­nanc­ing, with for­mer ex­ec­u­tives from Sur­face On­col­o­gy, Syn­dax and blue­bird bio at the helm.

Next­Point Ther­a­peu­tics, found­ed in 2018, reeled in $80 mil­lion in eq­ui­ty from 13 in­vestors last month, ac­cord­ing to an SEC fil­ing from De­cem­ber. A spokesper­son for Boston-based Next­Point de­clined to com­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER